Insmed

Insmed is a global biopharma company developing treatments for patients with serious and rare diseases. Its first commercial product, ARIKAYCE® (amikacin liposome inhalation suspension), is the first therapy approved in the US for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

ARIKAYCE® uses the company’s pulmonary liposomal drug delivery system, PULMOVANCE, which delivers the API directly to the site of infection by encapsulating water-soluble drug in the liposome’s water core.

Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Insmed was founded in 1988 and went public in 2000 (NASDAQ:INSM).